The level of vascular endothelial growth factor in peripheral blood of type 2 diabetic patients depending on kidney functional state

Keywords: diabetes mellitus, diabetic nephropathy, vascular endothelial growth factor

Abstract

Abstract. The aim of the study was to assess a serum level of vascular endothelial growth factor (VEGF) in type 2 diabetic patients depending on kidney function.

Methods: we examined 66 type 2 diabetic patients and 20 healthy control subjects. Depending on the presence of albuminuria and glomerular filtration rate (GFR) level, patients with diabetes mellitus (DM) were divided into the following groups: group I - patients with type 2 DM without signs of nephropathy – normal GFR without albuminuria (n = 26); group ІІ - patients with type 2 DM with normal GFR and albuminuria (n = 22); group III - patients with type 2 DM with reduced GFR and albuminuria (n = 18). ІV group - patients with acute coronary syndrome (n = 26).

The concentration of the VEGF was determined by enzyme-linked immunosorbent assay. The glomerular filtration rate (GFR) was calculated using the CKD EPI formula (KDIGO 2012).

Results: serum VEGF level in patients with diabetic nephropathy (DN) was significantly increased depending on kidney function.

VEGF positively correlated with urine albumin and serum creatinine levels and the negative correlation with GFR was found. These findings prove the undeniable role of kidneys in the development of renocardial syndrome in patients with DN. VEGF levels positively correlated with glycosylated hemoglobin and total cholesterol, indicating an unconditional dependence of endothelial dysfunction on lipid and glucose metabolism disorders.

Conclusions: Increased levels of VEGF in type 2 diabetic patients without clinical signs of kidney damage may indicate the development of subclinical renal dysfunction. Blood VEGF in patients with DN may be an integral marker of endothelial dysfunction and pathological angiogenesis. Our findings suggest that determination of serum VEGF level in patients with DN may have practical use as an early predictor of cardiac disruption, estimation of the prognosis, as well as improvement of cardionephroprotective strategy.

Downloads

Download data is not yet available.

References

Silvestre JS, Levy BI. Molecular basis of angiopathy in diabetes mellitus. Circ Res. 2006;98:4–6. doi: 10.1161/01.RES.0000200396.90220.41

Belovol AM, Knyazkova II. Serdechno-sosudictye zabolevaniya i saharnyi diabet/ Health Ua J. 2014;3(27):28-29. Available from: http://repo.knmu.edu.ua/handle/123456789/8535 [In Russian].

Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell. 2010;21:377–9. doi: 10.1091/mbc.E09-07-0591

Semenovykh P. S., Topchii I. I., Shcherban T. D., Masiy V. V., Kirienko A. N., Yakimenko Yu. S. Left ventricle structural and functional peculiarities in patients with diabetic nephropathy. Ukr J Med Biol Sport. 2018;3(7):154-8. doi: 10.26693/jmbs03.07.154 [In Ukrainian].

Topchii I. I., Semenovykh P. S.,  Galchinskaya V. Yu., Shcherban T. D., Yakimenko Yu. S. Renal functional reserve in patients with type 2 diabetes mellitus. Exper Clin Med. 2018;2-3(79-80):88-93. Available from: http://nbuv.gov.ua/UJRN/eikm_2018_2-3_15 [In Ukrainian].

Gavrilenko TI, Ryzhkova NA, Parkhomenko AN. Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic value. Ukr Cardiology J. 2011;4:87-95. Available from: http://journal.ukrcardio.org/wp-content/uploads/2011/04/14_4_2011.pdf [In Russian].

Schlingemann RO, Van Noorden CJ, Diekman MJ, et al. VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care. 2013;36:1629–34. doi: 10.2337/dc12-1951

Zhang Q., W. Fang, L. Ma, Z.-D. Wang, Y.M. Yang, Y.-Q. Lu VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes. Medicine (Baltimore). 2018;97(15):415. doi: 10.1097/MD.0000000000010415

Zorena K., Mys’liwska J., Mys’liwiec M. et al. Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus. J Hum Hypert. 2010;24:755-62. doi: 10.1038/jhh.2010.7

Trape J.C., Morales R., Molina X. et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand J Clin Lab Invest. 2006;663:261-7. doi: 10.1080/00365510600564949

Suzuki H., Murakami M., Shoji M. et al. Hepatocyte growth factor and vascular endothelial growth factor in ischemic heart disease. Coron Artery Dis. 2003;14:301-7. doi: 10.1097/00019501-200306000-00005

Shen M., Gao J., Jianan Li J., Su J. Effect of ischaemic exercise training of a normal limb on angiogenesis of a pathological ischaemic limb in rabbits. Cl Science. 2009;117:201-8. doi: 10.1042/CS20080212

Veron D, Bertuccio CA, Marlier A. et al. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia. 2011;54:1227–41. doi: 10.1007/s00125-010-2034-z

Mahdy RA, Nada WM, Hadhoud KM, et al. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye. 2010;24:1576–84. doi: 10.1038/eye.2010.86

Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol. 2007;27:144–52. doi:  10.1016/j.semnephrol.2007.01.009 

Liu CX, Hu Q, Wang Y, et al. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med. 2011;17:59–69. doi: 10.2119/molmed.2010.00111

Nakagawa T. Uncoupling of VEGF with NO as a mechanism for diabetic nephropathy. Diabetes Res Clin Pract. 2008;82(1):67–69. doi:  10.1016/j.diabres.2008.09.030     

Karalliedde J, Gnudi L. Endothelial factors and diabetic nephropathy. Diabetes Care. 2011;34(2):291–6. doi: 10.2337/dc11-s241

Chen J, Gu Z, Wu M, et al. C-reactive protein can upregulate VEGF expression to promote ADSC-induced angiogenesis by activating HIF-1alpha via CD64/PI3k/Akt and MAPK/ERK signaling pathways. Stem Cell Res Ther. 2016;7:114. doi: 10.1186/s13287-016-0377-1

Tian Y, Li JL, Hao L, et al. Association of cytokines, high sensitive C-reactive protein, VEGF and beta-defensin-1 gene polymorphisms and their protein expressions with chronic periodontitis in the Chinese population. Int J Biol Markers. 2013;28:Р.100–7. doi: 10.5301/jbm.5000010

Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27:195–207. doi: 10.1016/j.semnephrol.2007.01.012

 Veron D, Tufro A. VEGF and podocytes in diabetic nephropathy. J Am Soc Nephrol. 2012;32(4):385-93. doi: 10.1016/j.semnephrol.2012.06.010

Published
2019-02-22
How to Cite
Topchii, I., Shcherban, T., Galchinska, V., Semenovykh, P., & Savicheva, K. (2019). The level of vascular endothelial growth factor in peripheral blood of type 2 diabetic patients depending on kidney functional state. Ukrainian Journal of Nephrology and Dialysis, (1(61), 13-19. https://doi.org/10.31450/ukrjnd.1(61).2019.02